Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer

Jiale Gao(Capital Medical University), Zhongtao Zhang(Capital Medical University), Rui Xu(Nanjing Medical University), Zhigang Bai(Capital Medical University), Jiagang Han(Capital Medical University), Wei Deng(Capital Medical University), Yi Sun(Tianjin People's Hospital), Zhengyang Yang(Capital Medical University), Xiao Zhang(Capital Medical University), Gang Liu(Tianjin Medical University General Hospital), Ang Li(Shaanxi Provincial People's Hospital), Jie Zhang(Tongji University), Guangyong Chen(Wenzhou Medical University), Yishan Liu(Capital Medical University), Dalu Kong(Tianjin Medical University Cancer Institute and Hospital), Qi Wei(Tongji Hospital), Hongwei Yao(Capital Medical University)
Frontiers in Oncology
February 2, 2023
10.3389/fonc.2023.1057947
Cited by 21

Related Papers

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
Identification of Suitable Reference Genes for qPCR Analysis of Serum microRNA in Gastric Cancer Patients
|Digestive Diseases and Sciences|2011|269
Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial
|The Lancet Oncology|2021|184
A Multicenter Study on Etiology of Acute Pancreatitis in Beijing During 5 Years
|Pancreas|2014|147
CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade
|Cancer Discovery|2020|143